Europe gastric cancer diagnostics market is expected to gain market growth in the forecast period of 2021 to 2028. Data Bridge Market Research analyses that the market is growing with a CAGR of 6.9% in the forecast period of 2021 to 2028 and is expected to reach USD 371.76 million by 2028 from USD 228.01 million in 2020. The rising incidence of diabetes and growth of novel technological advancements for gastric cancer diagnostics assay are likely to be the major drivers which propel the demand of the market in the forecast period.

Stomach cancer is a type of cancer that starts in the stomach and spreads throughout the body. The stomach is a muscular pouch that lies immediately below your ribs in the upper part of your abdomen. Your stomach takes in and holds the food you eat before breaking it down and digesting it. Stomach cancer, commonly referred to as gastric cancer, can occur in any section of the stomach. Stomach cancers develop in the major section of the stomach in most parts of the world (stomach body). Various diagnostic tests used for diagnosis of cancer include prescreening tests, biopsy, biomarkers, imaging tests, PET/CT scan and ultrasound among others.

Increase in incidence of gastrointestinal tumors, lymphoma, and adenocarcinoma, Rise in alcohol consumptions and surge in smoking, increase in the geriatric population, strategic initiatives by key market players, recent advances in gastric cancer diagnostics is driving the market growth. However, high cost of testing and lack of sufficient financial support from health insurance policies is hampering the market growth. On the contrary, rising healthcare expenditure, adoption of automated systems, increased research and development on cancer diagnostics. Furthermore, stringent regulations and policies for approving the complicated nature of radiation devices and limitations of radiation tests.–62b55f93bb162f0ad2812b14–62b55fb638607d94da1dfe2f

Leave a Reply

Your email address will not be published.